XNAS
CARL
Market cap390mUSD
Oct 08, Last price
14.05USD
1D
-2.29%
1Q
18.07%
IPO
-2.77%
Name
Carlsmed Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
51m
+85.94%
Net income
-30m
L+22.17%
CFO
-29m
L+13.79%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
Key people
Sharon Schulzki
Chief Operating Officer
Shariq Hussain
Chief Information Officer
William Durall
Chief Commercial Officer · since 2024
Niall Casey
Co-Founder, Secretary, Director, Chief Intellectual Property Officer · since 2023
Michael Cordonnier
Chairman of the Board, President, Chief Executive Officer, Co-Founder · since 2023
Independent Director · since 2022
Independent Director · since 2024
Independent Director · since 2020
Kevin Sidow
Independent Director · since 2020
Philip Young
Independent Director · since 2020
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | |
| Income | |||
Revenues | |||
Cost of revenue | |||
Unusual Expense (Income) | |||
NOPBT | |||
NOPBT Margin | |||
Operating Taxes | |||
Tax Rate | |||
NOPAT | |||
Net income | |||
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | |||
BB yield | |||
| Debt | |||
Debt current | |||
Long-term debt | |||
Deferred revenue | |||
Other long-term liabilities | |||
Net debt | |||
| Cash flow | |||
Cash from operating activities | |||
CAPEX | |||
Cash from investing activities | |||
Cash from financing activities | |||
FCF | |||
| Balance | |||
Cash | |||
Long term investments | |||
Excess cash | |||
Stockholders' equity | |||
Invested Capital | |||
ROIC | |||
ROCE | |||
| EV | |||
Common stock shares outstanding | |||
Price | |||
Market cap | |||
EV | |||
EBITDA | |||
EV/EBITDA | |||
Interest | |||
Interest/NOPBT |